Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States
3TC lamivudine
ABC abacavir
ACOG American College of Obstetricians and Gynecologists
ALT alanine aminotransferase
anti-HBc hepatitis B core antibody
anti-HBs hepatitis B surface antibody
AOR adjusted odds ratio
AP antepartum
ART antiretroviral therapy
ARV antiretroviral
AST aspartate aminotransferase
ATV atazanavir
ATV/r atazanavir/ritonavir
AUC area under the curve
AZT zidovudine
BID twice daily
BMI body mass index
CBC complete blood count
CDC Centers for Disease Control and Prevention
CI confidence interval
Cmax maximum plasma concentration
Cmin minimum plasma concentration
CNS central nervous system
CVS chorionic villus sampling
CYP cytochrome P
CYP3A4 cytochrome P450 3A4
d4T stavudine
ddI didanosine
DMPA depot medroxyprogesterone acetate
DRV darunavir
DRV/r darunavir/ritonavir
DSMB Data and Safety Monitoring Board
EC enteric coated
ECG electrocardiogram
EFV efavirenz
EMS ethyl methane sulfonate
ETR etravirine
FDA Food and Drug Administration
FPV fosamprenavir
FPV/r fosamprenavir/ritonavir
FTC emtricitabine
gp glycoprotein
HAV hepatitis A virus
HBIG hepatitis B immune globulin
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HELLP hemolysis, elevated liver enzymes, and low platelets
HGC hard gel capsule
HR hazard ratio
HRSA Health Resources and Services Administration
IC50 inhibitory concentration 50%
IDV indinavir
IGF insulin-like growth factor
IP intrapartum
IQR interquartile range
IRIS immune reconstitution inflammatory syndrome
IUD intrauterine device
IV intravenous/intravenously
LPV/r lopinavir/ritonavir
MAC Mycobacterium avium complex
MACDP Metropolitan Atlanta Congenital Defects Program
MIRIAD Mother-Infant Rapid Intervention at Delivery (study)
MTCT mother-to-child transmission
mtDNA mitochondrial DNA
MVC maraviroc
NFV nelfinavir
NIH National Institutes of Health
NNRTI non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor
NtRTI nucleotide analogue reverse transcriptase inhibitor
NVP nevirapine
OC oral contraceptive
OI opportunistic infection
OR odds ratio
PACTG Pediatric AIDS Clinical Trials Group
PCP Pneumocystis jirovecii pneumonia
PCR polymerase chain reaction
PI protease inhibitor
PK pharmacokinetic
PMTCT prevention of mother-to-child transmission
PP postpartum
PPI proton pump inhibitor
PrEP pre-exposure prophylaxis
PTD preterm delivery
RAL raltegravir
RDS respiratory distress syndrome
RPV rilpivirine
RR relative risk
RTV ritonavir
sd single dose
SQ subcutaneous
SQV saquinavir
SQV/r saquinavir/ritonavir
STD sexually transmitted disease
T20 enfuvirtide
TDF tenofovir disoproxil fumarate
TDM therapeutic drug monitoring
TID three times daily
TPV tipranavir
TPV/r tipranavir/ritonavir
UGT uridine diphosphate glucuronosyltransferase
WHO World Health Organization
WITS Women and Infants Transmission Study
ZDV zidovudine